While the drug is approved for adults in the U.S., the European label covers patients 16 years of age and older. Pfizer bought Velsipity through its $6.7 billion Arena Pharmaceuticals acquisition.
TransMedics has the only FDA-approved multi-organ warm perfusion platform, giving it a competitive advantage in a niche ...
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of March. The chart below provides highlights of key monograph updates made ...